Sandra Nordmann1,2,3, Caroline Lions4,5,6, Antoine Vilotitch4,5,6, Laurent Michel7,8,9, Marion Mora4,5,6, Bruno Spire4,5,6, Gwenaelle Maradan4,5,6, Alain Morel10, Perrine Roux4,5,6, M Patrizia Carrieri4,5,6. 1. INSERM U912-ORS PACA, 27 boulevard Jean Moulin, 13005, Marseille, France. Sandra.nordmann@inserm.fr. 2. Université Aix Marseille, IRD, UMR-S912, Marseille, France. Sandra.nordmann@inserm.fr. 3. ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille, France. Sandra.nordmann@inserm.fr. 4. INSERM U912-ORS PACA, 27 boulevard Jean Moulin, 13005, Marseille, France. 5. Université Aix Marseille, IRD, UMR-S912, Marseille, France. 6. ORS PACA, Observatoire Régional de la Santé Provence Alpes Côte d'Azur, Marseille, France. 7. INSERM, Research Unit 669, Paris, France. 8. Université Paris-Sud and Université Paris Descartes, UMR-S0669, Paris, France. 9. Centre Pierre Nicole, Paris, France. 10. Oppelia, Paris, France.
Abstract
RATIONALE/ OBJECTIVES: Sleep disturbance is frequent in opioid-dependent patients. To date, no data are available about the impact of methadone maintenance treatment on sleep disturbance. Using 1-year follow-up data from the Methaville trial, we investigated the impact of methadone initiation and other correlates on sleep disturbance in opioid-dependent patients. METHODS: Sleep disturbance severity was evaluated using two items from different scales (Center for Epidemiological Studies Depression Scale for depression and Opiate Treatment Index). We assessed the effect of methadone and other correlates on sleep disturbance severity during follow-up (months 0, 6, and 12) using a mixed multinomial logistic regression model. RESULTS: We included 173 patients who had 1-year follow-up data on sleep disturbance, corresponding to 445 visits. At enrolment, 60.5 % reported medium to severe sleep disturbance. This proportion remained stable during methadone treatment: 54.0 % at month 6 and 55.4 % at month 12. The final multivariate model indicated that younger patients (odds ratio (OR) [95 % CI] 0.95 [0.90-1.00]), patients with pain (OR [95 % CI] 2.45 [1.13-5.32]), patients with high or very high nicotine dependence (OR [95 % CI] 5.89 [2.41-14.39]), and patients at suicidal risk (2.50 [1.13-5.52]) had a higher risk of severe sleep disturbance. Because of collinearity between suicidal risk and attention deficit hyperactivity disorder (ADHD) symptoms, ADHD was not associated with sleep disturbance in the final model. Receiving methadone treatment had no significant effect on sleep disturbance. CONCLUSIONS: Sleep disturbance is frequent among opioid-dependent patients. It can be regarded as an important signal of more complex psychiatric comorbidities such as suicidal risk and ADHD. However, sleep disturbance should not be considered an obstacle to methadone maintenance treatment (MMT) initiation or continuation.
RATIONALE/ OBJECTIVES:Sleep disturbance is frequent in opioid-dependent patients. To date, no data are available about the impact of methadone maintenance treatment on sleep disturbance. Using 1-year follow-up data from the Methaville trial, we investigated the impact of methadone initiation and other correlates on sleep disturbance in opioid-dependent patients. METHODS:Sleep disturbance severity was evaluated using two items from different scales (Center for Epidemiological Studies Depression Scale for depression and Opiate Treatment Index). We assessed the effect of methadone and other correlates on sleep disturbance severity during follow-up (months 0, 6, and 12) using a mixed multinomial logistic regression model. RESULTS: We included 173 patients who had 1-year follow-up data on sleep disturbance, corresponding to 445 visits. At enrolment, 60.5 % reported medium to severe sleep disturbance. This proportion remained stable during methadone treatment: 54.0 % at month 6 and 55.4 % at month 12. The final multivariate model indicated that younger patients (odds ratio (OR) [95 % CI] 0.95 [0.90-1.00]), patients with pain (OR [95 % CI] 2.45 [1.13-5.32]), patients with high or very high nicotine dependence (OR [95 % CI] 5.89 [2.41-14.39]), and patients at suicidal risk (2.50 [1.13-5.52]) had a higher risk of severe sleep disturbance. Because of collinearity between suicidal risk and attention deficit hyperactivity disorder (ADHD) symptoms, ADHD was not associated with sleep disturbance in the final model. Receiving methadone treatment had no significant effect on sleep disturbance. CONCLUSIONS:Sleep disturbance is frequent among opioid-dependent patients. It can be regarded as an important signal of more complex psychiatric comorbidities such as suicidal risk and ADHD. However, sleep disturbance should not be considered an obstacle to methadone maintenance treatment (MMT) initiation or continuation.
Authors: Michael Mancino; Geoffrey Curran; Xiaotong Han; Elise Allee; Keith Humphreys; Brenda M Booth Journal: Am J Drug Alcohol Abuse Date: 2010-05 Impact factor: 3.829
Authors: Stefan Cohrs; Andrea Rodenbeck; Dieter Riemann; Bertram Szagun; Andreas Jaehne; Jürgen Brinkmeyer; Gerhard Gründer; Thomas Wienker; Amalia Diaz-Lacava; Arian Mobascher; Norbert Dahmen; Norbert Thuerauf; Johannes Kornhuber; Falk Kiefer; Jürgen Gallinat; Michael Wagner; Dieter Kunz; Ulrike Grittner; Georg Winterer Journal: Addict Biol Date: 2012-08-23 Impact factor: 4.280
Authors: Geurt van de Glind; Wim van den Brink; Maarten W J Koeter; Pieter-Jan Carpentier; Katelijne van Emmerik-van Oortmerssen; Sharlene Kaye; Arvid Skutle; Eli-Torild H Bu; Johan Franck; Maija Konstenius; Franz Moggi; Geert Dom; Sofie Verspreet; Zsolt Demetrovics; Máté Kapitány-Fövény; Melina Fatséas; Marc Auriacombe; Arild Schillinger; Andrea Seitz; Brian Johnson; Stephen V Faraone; J Antoni Ramos-Quiroga; Miguel Casas; Steve Allsop; Susan Carruthers; Csaba Barta; Robert A Schoevers; Frances R Levin Journal: Drug Alcohol Depend Date: 2013-05-06 Impact factor: 4.492
Authors: Patrick H Finan; Chung Jung Mun; David H Epstein; William J Kowalczyk; Karran A Phillips; Daniel Agage; Michael T Smith; Kenzie L Preston Journal: Drug Alcohol Depend Date: 2019-11-18 Impact factor: 4.852
Authors: Daniel B Larach; Michael J Sahara; Sawsan As-Sanie; Stephanie E Moser; Andrew G Urquhart; Jules Lin; Afton L Hassett; Joseph A Wakeford; Daniel J Clauw; Jennifer F Waljee; Chad M Brummett Journal: Ann Surg Date: 2021-03-01 Impact factor: 13.787